Indivior Pharmaceuticals Quarterly Income Statement
NASDAQ: INDVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Indivior Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Indivior Pharmaceuticals generated $343.0 million in revenue, up 13.6% from the same quarter a year earlier. Net income was $122.0 million (+577.8% year over year), for a net margin of 35.6% versus a median of 17.7% in the prior 5 quarters. Gross margin was 85.7% (up from 82.8%) and operating margin 46.6%.
Diluted earnings per share came in at $0.98, up from $0.14.
Summary generated from market data by MetaCap's automated system. Methodology
Indivior Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 343.00M | 317.00M | 358.00M | 314.00M | 302.00M | 266.00M | 299.00M | 307.00M | 299.00M | 284.00M |
| Revenue growth (YoY) | +13.58% | +19.17% | +19.73% | +2.28% | +1.00% | -6.34% | — | — | — | — |
| Cost of Revenue | 50.00M | 40.00M | 67.00M | 83.00M | 52.00M | 44.00M | 48.00M | 66.00M | 79.00M | 38.00M |
| Gross Profit | 294.00M | 277.00M | 292.00M | 230.00M | 250.00M | 221.00M | 250.00M | 241.00M | 220.00M | 246.00M |
| Operating Expenses | 134.00M | 139.00M | 211.00M | 187.00M | 179.00M | 156.00M | 205.00M | 206.00M | 338.00M | 171.00M |
| Research & Development | 12.00M | 16.00M | 21.00M | 33.00M | 21.00M | 22.00M | 31.00M | 22.00M | 26.00M | 28.00M |
| Selling, General & Admin | 122.00M | 124.00M | 189.00M | 155.00M | 158.00M | 133.00M | 175.00M | 142.00M | 152.00M | 143.00M |
| Operating Income | 160.00M | 137.00M | 81.00M | 43.00M | 72.00M | 66.00M | 46.00M | 35.00M | -118.00M | 75.00M |
| Interest Expense | 2.00M | 7.00M | 6.00M | 12.00M | 15.00M | 12.00M | 13.00M | 11.00M | 9.00M | 9.00M |
| Pretax Income | 160.00M | 115.00M | 81.00M | 37.00M | 62.00M | 59.00M | 38.00M | 30.00M | -121.00M | 73.00M |
| Income Tax | 38.00M | 26.00M | -21.00M | -5.00M | 44.00M | 11.00M | 17.00M | 8.00M | -23.00M | 11.00M |
| Net Income | 122.00M | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M | 21.00M | 22.00M | -97.00M | 61.00M |
| Net Income growth (YoY) | +577.78% | +89.36% | +385.71% | +90.91% | — | -22.95% | — | — | — | — |
| EPS (Basic) | 1.02 | 0.71 | 0.81 | 0.34 | 0.15 | 0.38 | 0.16 | 0.16 | -0.72 | 0.45 |
| EPS (Diluted) | 0.98 | 0.69 | 0.79 | 0.33 | 0.14 | 0.38 | 0.16 | 0.16 | -0.72 | 0.45 |
| Shares Outstanding (Basic) | 119.00M | 124.00M | — | 125.00M | 125.00M | 124.00M | — | 132.00M | 135.00M | 136.00M |
| Shares Outstanding (Diluted) | 124.00M | 129.00M | — | 129.00M | 126.00M | 125.00M | — | 133.00M | 135.00M | 137.00M |
| EBITDA | 162.00M | 139.00M | 83.00M | 46.00M | 74.00M | 69.00M | 51.00M | 39.00M | -116.00M | 80.00M |
| Gross Margin | 85.71% | 87.38% | 81.56% | 73.25% | 82.78% | 83.08% | 83.61% | 78.50% | 73.58% | 86.62% |
| Operating Margin | 46.65% | 43.22% | 22.63% | 13.69% | 23.84% | 24.81% | 15.38% | 11.40% | -39.46% | 26.41% |
| Net Margin | 35.57% | 28.08% | 28.49% | 13.38% | 5.96% | 17.67% | 7.02% | 7.17% | -32.44% | 21.48% |
This table shows 10 quarterly periods of Indivior Pharmaceuticals's income statement, from Q2 2026 back to Q1 2024, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow INDV's reporting calendar. What is a income statement?